Stay updated with breaking news from Standard Deviation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The consensus price target hints at a 42.1% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 221.8% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Results of the phase 2 RISE UP trial offer additional perspective into the benefit-risk profile of mitapivat in patients with sickle cell disease.
Bezuclastinib, a targeted oral therapy, shows promise in reducing disease burden and improving symptoms by 50% or more in nonadvanced systemic mastocytosis patients, as revealed in the phase 2 SUMMIT trial data presented at ASH 2023.
A substudy of the ASCEND trial offers insight into the effects of omega-3 fatty acids use on risk of diabetic retinopathy in people with diabetes.